Krystal Biotech (KRYS) Capital Expenditures (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Capital Expenditures of $3.6 million for Q2 2026, up 87.24% year-over-year from $1.9 million in Q2 2025, and down 50.13% on a QoQ basis from $7.1 million in Q1 2026.
Krystal Biotech (KRYS) Capital Expenditures (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Capital Expenditures for 11 years, with the latest figure at $3.6 million in Q2 2026.
- Capital Expenditures for Q2 2026 came in at $3.6 million, up 87.24% year-over-year; the trailing twelve-month figure through Jun 2026 was $14.6 million (up 81.11% YoY), and the FY2025 annual result was $12.0 million, up 40.65% from the prior year.
- Capital Expenditures fell to $3.6 million in Q2 2026, from $7.1 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $17.2 million in Q1 2022 and troughed at -$867000.0 in Q2 2023.
- A 5-year average of $5.3 million and a median of $2.9 million in 2025 frame the typical range for Capital Expenditures.
- The widest annual swing landed in 2024, when Capital Expenditures slumped 362.86%; it then jumped 1600.0% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $5.2 million in 2022, then tumbled by 86.66% to $696000.0 in 2023, then plunged by 70.55% to $205000.0 in 2024, then surged by 943.41% to $2.1 million in 2025, then soared by 66.67% to $3.6 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $3.6 million in Q2 2026, $7.1 million in Q1 2026, and $2.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.57 Mn |
| Jun 30, 2026 | 3.57 Mn |
| Mar 31, 2026 | 7.15 Mn |
| Mar 31, 2026 | 7.15 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Sep 30, 2025 | -706,000.00 |
| Sep 30, 2025 | -706,000.00 |
| Jun 30, 2025 | -4.88 Mn |
| Jun 30, 2025 | -4.88 Mn |
| Mar 31, 2025 | 6.20 Mn |
| Mar 31, 2025 | 6.20 Mn |
| Dec 31, 2024 | 5.06 Mn |
| Dec 31, 2024 | 5.06 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Jun 30, 2024 | 7.31 Mn |
| Jun 30, 2024 | 7.31 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Mar 31, 2024 | 1.26 Mn |